Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Visiting This Japanese City Just Got A Little More Expensive (Here's What Travelers Should Know) - 2Rick Steves Prefers Paying A Bit Extra For This Delectable Food When Dining In Spain
- 3Starfront Observatories: A haven for distant stargazers
- 4Reality TV star Spencer Pratt, who lost his home in Palisades Fire, is running for mayor of Los Angeles
- 5The Best Games On the planet
- Curl Up With Some Hot Chocolate And Watch Mighty Car Mods Explore Japan In A Honda City Turbo II
- Key Business Regulations to Consider While Arranging Your Independent venture
- Game theory explains why reasonable parents make vaccine choices that fuel outbreaks
- Pick Your Number one breakfast food
- New heart disease calculator predicts 30-year risk for young adults
- How did humans evolve, and will we evolve more?
- Arctic is again the hottest it's been in 125 years, with record-low sea ice, NOAA report says
- Nick Reiner's defense attorney asks to be replaced, again delaying arraignment in connection with the stabbing deaths of his parents, Rob Reiner and Michele Singer Reiner
- The most effective method to Decide the Best Auto Crash Attorney for Your Lawful Necessities
